Showing 2411-2420 of 3315 results for "".
- Rayner Secures FDA Approval for RayOne EMV Toric IOLhttps://modernod.com/news/rayner-secures-fda-approval-for-rayone-emv-toric-iol/2484172/The FDA has approved Rayner's RayOne EMV Toric IOL following the completion of a pivotal investigational device exemption (IDE) study. According to Rayner, the RayOne EMV Toric lens has been enginee
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Modelhttps://modernod.com/news/nurexone-demonstrates-reproducible-dose-dependent-vision-recovery-in-preclinical-glaucoma-model/2484162/NurExone Biologic announced new preclinical results showing that its lead candidate ExoPTEN produces a reproducible, dose-dependent therapeutic effect in an eye model of glaucoma. The study, conducted in collaboration
- J&J to Present New Data Demonstrating Superiority of Acuvue Oasys Max 1-Day for Astigmatism at AAOpthttps://modernod.com/news/jj-to-present-new-data-demonstrating-superiority-of-acuvue-oasys-max-1-day-for-astigmatism-at-aaopt/2484158/Johnson & Johnson announced new clinical data demonstrating significantly higher end-of-day comfort and stronger overall patient preference for the Acuvue Oasys Max 1-Day for Astigmatism contact lenses compared to Dailies Total1 for Astigmatism.
- EyeDura Therapeutics Partners with SERI to Advance Insulin-Based Topical Therapy for Neurotrophic Keratitishttps://modernod.com/news/eyedura-therapeutics-partners-with-seri-to-advance-insulin-based-topical-therapy-for-neurotrophic-keratitis/2484157/EyeDura Therapeutics has initiated preclinical efficacy studies in collaboration with the Singapore Eye Research Institute (SERI). The studies will advance the company’s lead insulin-based eye drop treatment for neurotrophic keratitis (NK), a rare, degen
- Cirrus Therapeutics Raises $11 Million to Advance First-in-Class Ocular Gene Therapy Targeting Dry AMDhttps://modernod.com/news/cirrus-therapeutics-raises-11-million-to-advance-first-in-class-ocular-gene-therapy-targeting-dry-amd/2484149/Cirrus Therapeutics announced the close of an $11 million seed financing round to advance its gene and cell therapy pipeline. The company will use the funds to progress its lead program into IND-enabling studies.
- Inflammasome Therapeutics Reports Encouraging Early Results for K8 in Geographic Atrophyhttps://modernod.com/news/inflammasome-therapeutics-reports-encouraging-early-results-for-k8-in-geographic-atrophy/2484139/Inflammasome Therapeutics, which is developing a new class of inflammasome inhibitors known as Kamuvudines, announced promising early clinical data for its lead ophthalmic candidate K8. Delivered via a sustained-release intraocular implant, K8 reduced geograph
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Nanoscope Secures EMA Orphan Designations and FDA RMAT Status for Retinal Gene Therapy MCO-010https://modernod.com/news/nanoscope-secures-ema-orphan-designations-and-fda-rmat-status-for-retinal-gene-therapy-mco-010/2484130/Nanoscope Therapeutics announced regulatory milestones in both Europe and the United States for its lead gene therapy candidate, MCO-010 (sonpiretigene isteparvovec). The European Medicines Agency (EMA) has granted Orphan D
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr